MBX Biosciences Cash Flow Statement
NASDAQ: MBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
53.24-0.01 (-0.02%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MBX Biosciences free cash flow
In fiscal 2025, MBX Biosciences generated -$79.9 million of operating cash flow and spent $1.9 million on capital expenditures. That left free cash flow of -$81.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
MBX Biosciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -86.97M | -61.92M | -32.56M |
| Net Income growth (YoY) | — | — | — |
| Depreciation & Amortization | 248.00K | 244.00K | 157.00K |
| Stock-Based Compensation | 8.68M | 5.22M | 2.04M |
| Change in Working Capital | 4.35M | 7.10M | 449.00K |
| Operating Cash Flow | -79.95M | -54.68M | -31.98M |
| Capital Expenditures | -1.93M | -874.00K | -129.00K |
| Investing Cash Flow | -83.70M | -160.59M | -30.93M |
| Financing Cash Flow | 189.59M | 234.10M | 69.22M |
| Net Change in Cash | 25.94M | 18.83M | 6.31M |
| Free Cash Flow | -81.88M | -55.55M | -32.11M |
This table shows 3 annual periods of MBX Biosciences's cash flow statement, from FY 2025 back to FY 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MBX's reporting calendar. What is a cash flow statement?